Secremet

Secremet is a fixed-dose combination oral hypoglycemic medication developed and marketed by Bal Pharma Limited. It contains two active pharmaceutical ingredients: glimepiride, a second-generation sulfonylurea, and metformin, a biguanide. Although Bal Pharma lists Secremet under its Servetus Division, which is dedicated to cardiac care, the drug is primarily indicated for the management of type 2 diabetes mellitus. Glimepiride functions by stimulating insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. This combination is typically prescribed when glycemic control is inadequate with monotherapy. The classification under a cardiac division likely reflects the significant overlap between diabetic management and cardiovascular risk reduction in clinical practice.

Brand names

Secremet

Other names

glimepiride + metformin